Medofloran

Terbinafine, the active ingredient in Medofloran, is a allylamine antifungal presented as an oral tablet for oral use. It treats dermatophyte infections such as athlete's foot, ringworm, jock itch and fungal nail disease in adults.

GNH USA supplies Medofloran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medofloran (terbinafine) is used to treat superficial and nail fungal infections caused by dermatophytes. - Tinea pedis (athlete's foot): reduces itching and clears skin infection. - Tinea corporis (ringworm): eliminates the rash and prevents spread. - Tinea cruris (jock itch): relieves irritation and resolves infection. - Onychomycosis (fungal nail infection): improves nail appearance and eradicates the fungus.

Adverse reactions to Medofloran may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Skin reactions: mild rash or pruritus. - Headache: transient mild headache. - Elevated liver enzymes: mild, reversible increases in hepatic transaminases. - Taste disturbances: temporary loss of taste or bitter taste.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or elevated bilirubin. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia or eosinophilia. - Peripheral neuropathy: numbness or tingling in extremities. - Anaphylaxis: acute allergic reaction with respiratory distress.

Before prescribing Medofloran, clinicians should consider several safety aspects. - Liver function: assess baseline hepatic enzymes and monitor during therapy. - Renal impairment: adjust use in patients with severe kidney disease. - Drug interactions: review concomitant medications that affect liver metabolism. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Age considerations: use caution in elderly patients due to potential comorbidities. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Terbinafine may alter the plasma levels of several co‑administered drugs.

Major Interactions (Avoid): - CYP2D6 substrates: increased risk with antidepressants such as fluoxetine. - Warfarin: enhanced anticoagulant effect, may require INR monitoring. - Cyclosporine: heightened nephrotoxicity risk.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise terbinafine concentrations. - Oral contraceptives: possible reduction in efficacy. - Rifampicin: may decrease terbinafine levels, reducing effectiveness.